よむ、つかう、まなぶ。
10参考資料１－２ 成人用肺炎球菌ワクチンファクトシート［4.9MB］ (45 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_70339.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第64回 2／12）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
167.
Hoshi SL, Shono A, Seposo X, Okubo R, Kondo M. Cost-effectiveness analyses of 15- and 20-valent
pneumococcal conjugate vaccines for Japanese elderly. Vaccine 2022; 40(49): 7057-64.
168.
Kang DW, Kim CR, Song JY, Park SK. Cost-effectiveness of the 20-valent pneumococcal conjugate
vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea. Vaccine
2024; 42(4): 871-8.
169.
Malene BM, Oyvind H, Tor M, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine
compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting. Cost Eff
Resour Alloc 2023; 21(1): 52.
170.
Marbaix S, Mignon A, Taelman A, Averin A, Atwood M, Vietri J. Cost-utility of 20-valent
pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among
Belgian adults. Expert Rev Vaccines 2023; 22(1): 1008-21.
171.
Mendes D, Averin A, Atwood M, et al. Cost-effectiveness of using a 20-valent pneumococcal
conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev
Pharmacoecon Outcomes Res 2022; 22(8): 1285-95.
172.
Nakamura S, Mikami M, Hayamizu T, et al. Cost-effectiveness analysis of adult pneumococcal
conjugate vaccines for pneumococcal disease in Japan. Expert Rev Vaccines 2024; 23(1): 546-60.
173.
Olsen J, Schnack H, Skovdal M, Vietri J, Mikkelsen MB, Poulsen PB. Cost-effectiveness of 20-valent
pneumococcal conjugate vaccine in Denmark compared with PPV23. J Med Econ 2022; 25(1): 1240-54.
174.
Rey-Ares L, Averin A, Mac Mullen M, et al. Cost-Effectiveness of 20-Valent Pneumococcal
Conjugate Vaccine in Argentinean Adults. Infect Dis Ther 2024; 13(6): 1235-51.
175.
Restivo V, Baldo V, Sticchi L, et al. Cost-Effectiveness of Pneumococcal Vaccination in Adults in
Italy: Comparing New Alternatives and Exploring the Role of GMT Ratios in Informing Vaccine Effectiveness.
Vaccines 2023; 11(7): 1253.
176.
Rosenthal M, Stoecker C, Leidner AJ, Cho BH, Pilishvili T, Kobayashi M. Cost-effectiveness of 15-
valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years
and older with underlying conditions. Vaccine 2025; 44: 126567.
177.
Smith KJ, Wateska AR, Nowalk MP, et al. Cost-Effectiveness of Newly Recommended Pneumococcal
Vaccination Strategies in Older Underserved Minority Adults in the USA. Infect Dis Ther 2022; 11(4): 168393.
178.
Wateska AR, Patricia Nowalk M, Lin CJ, et al. Cost-effectiveness of revised US pneumococcal
vaccination recommendations in underserved minority adults < 65-years-old. Vaccine 2022; 40(50): 7312-20.
179.
Wateska AR, Nowalk MP, Altawalbeh SM, et al. Changes in the cost-effectiveness of pneumococcal
vaccination and of programs to increase its uptake in U.S. older adults. J Am Geriatr Soc 2024; 72(8): 2423-33.
180.
Australian Government Department of Health and Aged Care. Pneumococcal disease. 2024/8/16.
https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/pneumococcal-disease
(accessed 2025/4/4).
181.
European Centre for Disease Prevention and Control. Vaccine Scheduler Pneumococcal Disease:
Recommended vaccinations. https://vaccine-
45
Hoshi SL, Shono A, Seposo X, Okubo R, Kondo M. Cost-effectiveness analyses of 15- and 20-valent
pneumococcal conjugate vaccines for Japanese elderly. Vaccine 2022; 40(49): 7057-64.
168.
Kang DW, Kim CR, Song JY, Park SK. Cost-effectiveness of the 20-valent pneumococcal conjugate
vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea. Vaccine
2024; 42(4): 871-8.
169.
Malene BM, Oyvind H, Tor M, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine
compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting. Cost Eff
Resour Alloc 2023; 21(1): 52.
170.
Marbaix S, Mignon A, Taelman A, Averin A, Atwood M, Vietri J. Cost-utility of 20-valent
pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among
Belgian adults. Expert Rev Vaccines 2023; 22(1): 1008-21.
171.
Mendes D, Averin A, Atwood M, et al. Cost-effectiveness of using a 20-valent pneumococcal
conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev
Pharmacoecon Outcomes Res 2022; 22(8): 1285-95.
172.
Nakamura S, Mikami M, Hayamizu T, et al. Cost-effectiveness analysis of adult pneumococcal
conjugate vaccines for pneumococcal disease in Japan. Expert Rev Vaccines 2024; 23(1): 546-60.
173.
Olsen J, Schnack H, Skovdal M, Vietri J, Mikkelsen MB, Poulsen PB. Cost-effectiveness of 20-valent
pneumococcal conjugate vaccine in Denmark compared with PPV23. J Med Econ 2022; 25(1): 1240-54.
174.
Rey-Ares L, Averin A, Mac Mullen M, et al. Cost-Effectiveness of 20-Valent Pneumococcal
Conjugate Vaccine in Argentinean Adults. Infect Dis Ther 2024; 13(6): 1235-51.
175.
Restivo V, Baldo V, Sticchi L, et al. Cost-Effectiveness of Pneumococcal Vaccination in Adults in
Italy: Comparing New Alternatives and Exploring the Role of GMT Ratios in Informing Vaccine Effectiveness.
Vaccines 2023; 11(7): 1253.
176.
Rosenthal M, Stoecker C, Leidner AJ, Cho BH, Pilishvili T, Kobayashi M. Cost-effectiveness of 15-
valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years
and older with underlying conditions. Vaccine 2025; 44: 126567.
177.
Smith KJ, Wateska AR, Nowalk MP, et al. Cost-Effectiveness of Newly Recommended Pneumococcal
Vaccination Strategies in Older Underserved Minority Adults in the USA. Infect Dis Ther 2022; 11(4): 168393.
178.
Wateska AR, Patricia Nowalk M, Lin CJ, et al. Cost-effectiveness of revised US pneumococcal
vaccination recommendations in underserved minority adults < 65-years-old. Vaccine 2022; 40(50): 7312-20.
179.
Wateska AR, Nowalk MP, Altawalbeh SM, et al. Changes in the cost-effectiveness of pneumococcal
vaccination and of programs to increase its uptake in U.S. older adults. J Am Geriatr Soc 2024; 72(8): 2423-33.
180.
Australian Government Department of Health and Aged Care. Pneumococcal disease. 2024/8/16.
https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/pneumococcal-disease
(accessed 2025/4/4).
181.
European Centre for Disease Prevention and Control. Vaccine Scheduler Pneumococcal Disease:
Recommended vaccinations. https://vaccine-
45